James A Triccas

List of Publications by Year
in descending order

101 papers	7,259 citations	126907 33 h-index	71685 76 g-index
115 all docs	115 docs citations	115 times ranked	11453 citing authors

#	Article	IF	Citations
1	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe, The, 2022, 3, e52-e61.	7.3	436
2	Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. Clinical Infectious Diseases, 2022, 75, e878-e879.	5.8	20
3	Rough and smooth variants of Mycobacterium abscessus are differentially controlled by host immunity during chronic infection of adult zebrafish. Nature Communications, 2022, 13, 952.	12.8	23
4	High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens. Microbiology Spectrum, 2022, 10, e0169521.	3.0	8
5	Virulence Mechanisms of Mycobacterium abscessus: Current Knowledge and Implications for Vaccine Design. Frontiers in Microbiology, 2022, 13, 842017.	3.5	9
6	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. Nature Reviews Immunology, 2022, 22, 387-397.	22.7	93
7	Characterization of the Protective Immune Responses Conferred by Recombinant BCG Overexpressing Components of Mycobacterium tuberculosis Sec Protein Export System. Vaccines, 2022, 10, 945.	4.4	3
8	Synthesis and evaluation of pyridine-derived bedaquiline analogues containing modifications at the A-ring subunit. RSC Medicinal Chemistry, 2021, 12, 943-959.	3.9	5
9	Intrapulmonary vaccination with delta-inulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction. Mucosal Immunology, 2021, 14, 762-773.	6.0	8
10	Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity. Vaccine, 2021, 39, 1990-1996.	3.8	4
11	TCR Affinity Controls the Dynamics but Not the Functional Specification of the Antimycobacterial CD4+ T Cell Response. Journal of Immunology, 2021, 206, 2875-2887.	0.8	5
12	Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display. ACS Central Science, 2021, 7, 1001-1008.	11.3	47
13	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 1205-1211.	30.7	3,133
14	Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics. Frontiers in Immunology, 2021, 12, 740117.	4.8	10
15	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. Npj Vaccines, 2021, 6, 143.	6.0	47
16	Boosting BCG with recombinant influenza A virus tuberculosis vaccines increases pulmonary T cell responses but not protection against Mycobacterium tuberculosis infection. PLoS ONE, 2021, 16, e0259829.	2.5	3
17	Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. Antibiotics, 2020, 9, 523.	3.7	12
18	Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis. Npj Vaccines, 2020, 5, 105.	6.0	45

#	Article	IF	Citations
19	Adjuvant Strategies for More Effective Tuberculosis Vaccine Immunity. Microorganisms, 2019, 7, 255.	3.6	28
20	Structureâ€"Activity Relationships of <i>cyclo</i>(<scp>l</scp>-Tyrosyl-<scp>l</scp>-tyrosine) Derivatives Binding to <i>Mycobacterium tuberculosis</i> CYP121: Iodinated Analogues Promote Shift to High-Spin Adduct. Journal of Medicinal Chemistry, 2019, 62, 9792-9805.	6.4	19
21	Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery. Pharmaceutics, 2019, 11, 555.	4.5	16
22	Bengamides display potent activity against drug-resistant Mycobacterium tuberculosis. Scientific Reports, 2019, 9, 14396.	3.3	10
23	The generation of Tâ€cell memory to protect against tuberculosis. Immunology and Cell Biology, 2019, 97, 656-663.	2.3	23
24	Deciphering protective immunity against tuberculosis: implications for vaccine development. Expert Review of Vaccines, 2019, 18, 353-364.	4.4	22
25	Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis. Vaccine, 2018, 36, 2619-2629.	3.8	16
26	Organometallic Conjugates of the Drug Sulfadoxine for Combatting Antimicrobial Resistance. Chemistry - A European Journal, 2018, 24, 10078-10090.	3.3	28
27	A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans. Nature Communications, 2018, 9, 85.	12.8	49
28	Antitubercular Bis-Substituted Cyclam Derivatives: Structureâ€"Activity Relationships and in Vivo Studies. Journal of Medicinal Chemistry, 2018, 61, 3595-3608.	6.4	33
29	Broad activity of diphenyleneiodonium analogues against Mycobacterium tuberculosis, malaria parasites and bacterial pathogens. European Journal of Medicinal Chemistry, 2018, 148, 507-518.	5.5	14
30	Frontispiece: Organometallic Conjugates of the Drug Sulfadoxine for Combatting Antimicrobial Resistance. Chemistry - A European Journal, 2018, 24, .	3.3	0
31	Pulmonary immunization with a recombinant influenza A virus vaccine induces lung-resident CD4+ memory T cells that are associated with protection against tuberculosis. Mucosal Immunology, 2018, 11, 1743-1752.	6.0	48
32	New tuberculosis drug leads from naturally occurring compounds. International Journal of Infectious Diseases, 2017, 56, 212-220.	3.3	72
33	Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection. Scientific Reports, 2017, 7, 8582.	3.3	57
34	Functional Interplay between Type I and II Interferons Is Essential to Limit Influenza A Virus-Induced Tissue Inflammation. PLoS Pathogens, 2016, 12, e1005378.	4.7	54
35	Nontoxic Metalâ€"Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant <i>Mycobacterium tuberculosis</i>. Journal of Medicinal Chemistry, 2016, 59, 5917-5921.	6.4	42
36	The Ag85B protein of the BCG vaccine facilitates macrophage uptake but is dispensable for protection against aerosol Mycobacterium tuberculosis infection. Vaccine, 2016, 34, 2608-2615.	3.8	14

#	Article	IF	Citations
37	Influence of phthiocerol dimycocerosate on CD4+ T cell priming and persistence during Mycobacterium tuberculosis infection. Tuberculosis, 2016, 99, 25-30.	1.9	1
38	Novel vaccination approaches to prevent tuberculosis in children. Pneumonia (Nathan Qld), 2016, 8, 18.	6.1	11
39	Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice. Npj Vaccines, 2016, 1, 16012.	6.0	24
40	Development and delivery of anti-tuberculosis drugs, vaccines and immunotherapeutics. Advanced Drug Delivery Reviews, 2016, 102, 1-2.	13.7	2
41	An inducible expression system for high-level expression of recombinant proteins in slow growing mycobacteria. Plasmid, 2015, 81, 27-31.	1.4	4
42	Epitopeâ€specific CD4⁺, but not CD8⁺, Tâ€cell responses induced by recombinant influenza A viruses protect against <i>Mycobacterium tuberculosis</i> infection. European Journal of Immunology, 2015, 45, 780-793.	2.9	28
43	Homogentisate 1-2-Dioxygenase Downregulation in the Chronic Persistence of Pseudomonas aeruginosa Australian Epidemic Strain-1 in the CF Lung. PLoS ONE, 2015, 10, e0134229.	2.5	7
44	Potent Antimycobacterial Activity of the Pyridoxal Isonicotinoyl Hydrazone Analog 2-Pyridylcarboxaldehyde Isonicotinoyl Hydrazone: A Lipophilic Transport Vehicle for Isonicotinic Acid Hydrazide. Molecular Pharmacology, 2014, 85, 269-278.	2.3	33
45	Non-classical Î²-carbonic anhydrase inhibitors-towards novel anti-mycobacterials. MedChemComm, 2014, 5, 1563-1566.	3.4	8
46	Neuroprotective peptideâ€“macrocycle conjugates reveal complex structureâ€“activity relationships in their interactions with amyloid Î². Metallomics, 2014, 6, 1931-1940.	2.4	20
47	Efficient Synthesis and Anti-Tubercular Activity of a Series of Spirocycles: An Exercise in Open Science. PLoS ONE, 2014, 9, e111782.	2.5	14
48	Modulation of gene expression by Pseudomonas aeruginosa during chronic infection in the adult cystic fibrosis lung. Microbiology (United Kingdom), 2013, 159, 2354-2363.	1.8	19
49	Host Cellâ€“Induced Components of the Sulfate Assimilation Pathway Are Major Protective Antigens of Mycobacterium tuberculosis. Journal of Infectious Diseases, 2013, 207, 778-785.	4.0	12
50	Incorporation of Bulky and Cationic Cyclamâ€Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity. ChemistryOpen, 2013, 2, 99-105.	1.9	12
51	Influenza A Virus Infection Impairs Mycobacteria-Specific T Cell Responses and Mycobacterial Clearance in the Lung during Pulmonary Coinfection. Journal of Immunology, 2013, 191, 302-311.	0.8	29
52	Harnessing Single Cell Sorting to Identify Cell Division Genes and Regulators in Bacteria. PLoS ONE, 2013, 8, e60964.	2.5	27
53	Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation. Journal of Hepatology, 2012, 57, 352-358.	3.7	46
54	Pseudomonas aeruginosa strains from the chronically infected cystic fibrosis lung display increased invasiveness of A549 epithelial cells over time. Microbial Pathogenesis, 2012, 53, 37-43.	2.9	9

#	Article	IF	Citations
55	Protective immunity afforded by attenuated, PhoP<i>â€</i>deficient <i>Mycobacterium tuberculosis</i> is associated with sustained generation of CD4⁺ Tâ€cell memory. European Journal of Immunology, 2012, 42, 385-392.	2.9	46
56	The Secreted Lipoprotein, MPT83, of Mycobacterium tuberculosis Is Recognized during Human Tuberculosis and Stimulates Protective Immunity in Mice. PLoS ONE, 2012, 7, e34991.	2.5	30
57	Targeted induction of antigen expression within dendritic cells modulates antigen-specific immunity afforded by recombinant BCG. Vaccine, 2011, 29, 1374-1381.	3.8	14
58	Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis. Vaccine, 2011, 29, 7759-7765.	3.8	11
59	Cutaneous immunosurveillance by self-renewing dermal Î³Î´ T cells. Journal of Experimental Medicine, 2011, 208, 505-518.	8.5	248
60	Immunity toMycobacterium tuberculosis. Clinical and Developmental Immunology, 2011, 2011, 1-2.	3.3	0
61	Modulation of pulmonary DC function by vaccineâ€encoded GMâ€CSF enhances protective immunity against <i>Mycobacterium tuberculosis</i> infection. European Journal of Immunology, 2010, 40, 153-161.	2.9	50
62	Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis, 2010, 90, 354-360.	1.9	92
63	The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses. Immunology Letters, 2010, 130, 36-42.	2.5	11
64	Recombinant BCG as a vaccine vehicle to protect against tuberculosis. Bioengineered Bugs, 2010, 1, 110-115.	1.7	12
65	In vivo persistence and protective efficacy of the Bacille Calmette GuÃ©rin vaccine overexpressing the HspX latency antigen. Bioengineered Bugs, 2010, 1, 61-65.	1.7	19
66	Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine. Vaccine, 2010, 28, 1341-1346.	3.8	16
67	Antigen Load Governs the Differential Priming of CD8 T Cells in Response to the Bacille Calmette Guelrin Vaccine or <i>Mycobacterium tuberculosis</i> Infection. Journal of Immunology, 2009, 182, 7172-7177.	0.8	66
68	Heterologous Expression of Genes in Mycobacteria. Methods in Molecular Biology, 2009, 465, 243-253.	0.9	5
69	Challenge of developing new tuberculosis vaccines to generate life-long protective immunity. Expert Review of Vaccines, 2009, 8, 823-825.	4.4	8
70	Infectious diseases: Too little, too late for tuberculosis. Immunology and Cell Biology, 2008, 86, 293-294.	2.3	5
71	Migratory Dermal Dendritic Cells Act as Rapid Sensors of Protozoan Parasites. PLoS Pathogens, 2008, 4, e1000222.	4.7	213
72	Improved Protection against Disseminated Tuberculosis byMycobacterium bovisBacillus Calmette-GuÃ©rin Secreting Murine GM-CSF Is Associated with Expansion and Activation of APCs. Journal of Immunology, 2007, 179, 8418-8424.	0.8	41

#	Article	IF	Citations
73	Secretion of Functional Monocyte Chemotactic Protein 3 by Recombinant Mycobacterium bovis BCG Attenuates Vaccine Virulence and Maintains Protective Efficacy against M. tuberculosis Infection. Infection and Immunity, 2007, 75, 523-526.	2.2	17
74	Effects of DNA- and <i>Mycobacterium bovis</i> BCG-Based Delivery of the Flt3 Ligand on Protective Immunity to <i>Mycobacterium tuberculosis</i>. Infection and Immunity, 2007, 75, 5368-5375.	2.2	30
75	Plasmid Interleukin-23 (IL-23), but Not Plasmid IL-27, Enhances the Protective Efficacy of a DNA Vaccine against Mycobacterium tuberculosis Infection. Infection and Immunity, 2006, 74, 557-565.	2.2	71
76	Contribution of <scp>L</scp>â€Alanine Dehydrogenase to <i>In Vivo</i> Persistence and Protective Efficacy of the BCG Vaccine. Microbiology and Immunology, 2006, 50, 805-810.	1.4	5
77	Epitope-tagging vectors for the expression and detection of recombinant proteins in mycobacteria. Plasmid, 2005, 53, 269-273.	1.4	17
78	The Trifunctional Sulfate-activating Complex (SAC) of Mycobacterium tuberculosis. Journal of Biological Chemistry, 2005, 280, 7861-7866.	3.4	27
79	Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine, 2005, 23, 1680-1685.	3.8	37
80	The Mycobacterium tuberculosis cysD and cysNC genes form a stress-induced operon that encodes a tri-functional sulfate-activating complex. Microbiology (United Kingdom), 2004, 150, 1681-1686.	1.8	75
81	Mycobacterium tuberculosisDefective in Phthiocerol Dimycocerosate Translocation Provides Greater Protective Immunity against Tuberculosis than the Existing Bacille Calmetteâ€GuÃ©rin Vaccine. Journal of Infectious Diseases, 2004, 189, 105-112.	4.0	44
82	Recombinant Mycobacterium bovis bacillus Calmette-GuÃ©rin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clinical and Experimental Immunology, 2004, 137, 24-34.	2.6	66
83	Identification of strong promoter elements ofMycobacterium smegmatisand their utility for foreign gene expression in mycobacteria. FEMS Microbiology Letters, 2003, 224, 139-142.	1.8	13
84	Coexpression of Interleukin-12 Chains by a Self-Splicing Vector Increases the Protective Cellular Immune Response of DNA and Mycobacterium bovis BCG Vaccines against Mycobacterium tuberculosis. Infection and Immunity, 2002, 70, 1949-1956.	2.2	49
85	Destabilized green fluorescent protein for monitoring transient changes inÂmycobacterial gene expression. Research in Microbiology, 2002, 153, 379-383.	2.1	16
86	Comparative affects of plasmidâ€encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. Immunology and Cell Biology, 2002, 80, 346-350.	2.3	34
87	Analysis of stress- and host cell-induced expression of the Mycobacterium tuberculosis inorganic pyrophosphatase. BMC Microbiology, 2001, 1, 3.	3.3	13
88	Analysis of the Phthiocerol Dimycocerosate Locus ofMycobacterium tuberculosis. Journal of Biological Chemistry, 2001, 276, 19845-19854.	3.4	335
89	Isolation of strong expression signals of Mycobacterium tuberculosis. Microbiology (United) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf	1.8	20
90	Life on the inside: Probing Mycobacterium tuberculosis gene expression during infection. Immunology and Cell Biology, 2000, 78, 311-317.	2.3	23

#	Article	IF	Citations
91	Protection against Virulent Mycobacterium avium Infection following DNA Vaccination with the 35-Kilodalton Antigen Is Accompanied by Induction of Gamma Interferon-Secreting CD4 + T Cells. Infection and Immunity, 2000, 68, 3090-3096.	2.2	31
92	Use of fluorescence induction and sucrose counterselection to identify Mycobacterium tuberculosis genes expressed within host cells. Microbiology (United Kingdom), 1999, 145, 2923-2930.	1.8	68
93	An inducible expression system permitting the efficient purification of a recombinant antigen fromMycobacterium smegmatis. FEMS Microbiology Letters, 1998, 167, 151-156.	1.8	132
94	Molecular and Immunological Analyses of the Mycobacterium avium Homolog of the Immunodominant Mycobacterium leprae 35-Kilodalton Protein. Infection and Immunity, 1998, 66, 2684-2690.	2.2	33
95	Specific Serological Diagnosis of Leprosy with a Recombinant Mycobacterium leprae Protein Purified from a Rapidly Growing Mycobacterial Host. Journal of Clinical Microbiology, 1998, 36, 2363-2365.	3.9	14
96	A novel levansucraseâ€“levanase gene cluster in Bacillus stearothermophilus ATCC12980. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1997, 1353, 203-208.	2.4	24
97	Expression of Mycobacterium tuberculosis MPT64 in recombinant Myco. smegmatis : purification, immunogenicity and application to skin tests for tuberculosis. Clinical and Experimental Immunology, 1996, 103, 226-232.	2.6	77
98	Characterization of the gene encoding the immunodominant 35 kDa protein of Mycobacterium leprae. Molecular Microbiology, 1995, 16, 865-876.	2.5	58
99	BCG vaccination against tuberculosis: past disappointments and future hopes. Trends in Microbiology, 1995, 3, 397-401.	7.7	85
100	Differential T Cell Responses To Mycobacteria-Secreted Proteins Distinguish Vaccination With Bacille Calmette-Guerin From Infection With Mycobacterium Tuberculosis. Journal of Infectious Diseases, 1994, 170, 1326-1330.	4.0	78
101	The Constituents of the Cell Envelope and Their Impact on the Host Immune System. , 0, , 249-270.		2